|Tested species reactivity||Human, Mouse, Rat|
|Host / Isotype||Rabbit / IgG|
|Immunogen||A 13 amino acid peptide from near the carboxy terminus of human GPR3.|
|Purification||Antigen affinity chromatography|
|Contains||0.02% sodium azide|
|Storage Conditions||Maintain refrigerated at 2-8°C for up to 3 months. For long term storage store at -20°C|
|Tested Applications||Dilution *|
|Immunocytochemistry (ICC)||20 ug/ml|
|Immunofluorescence (IF)||20 ug/ml|
|Immunohistochemistry (IHC)||2.5 µg/ml|
|Western Blot (WB)||1-2 ug/ml|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
A suggested positive control is EL4 cell lysate.
PA5-20751 can be used with blocking peptide PEP-0865.
GPR3, also known as ACCA, is a G-protein coupled receptor that constitutively activates adenylate cyclase and is highly expressed in the central nervous system. Overexpression of GPR3 stimulates the production of amyloid-beta peptide (Abeta), the deposition of which is one of the pathological hallmarks of Alzheimer and quote;s disease (AD), while the ablation of GPR3 prevented the accumulation of Abeta in vitro and in an AD mouse model. This is of particular interest because of the proximity of a reported candidate Alzheimer and quote;s disease (AD) locus, suggesting that GPR3 may be a potential therapeutic target for the treatment of AD. GPR3 has also been shown to block the proliferation of cerebellar granule cell precursors (GCP) during postnatal development by inhibiting the Shh-induced proliferation of GCP, indicating that GPR3 activation may represent one of the signals that triggers the postnatal cell cycle exit and terminal differentiation of GPCs.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.